Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low

Acta Cardiologica

Volumn 73, Issue 4, 2018, Pages 335-341

  Verbrugge, Frederik H ^a   Martens, Pieter ^a,b   Boonen, Levinia ^a   Nijst, Petra ^a,b   Verhaert, David ^a   Noyens, Patrick ^a   De Vusser, Philip ^a   Dupont, Matthias ^a   Tang, W H Wilson ^c   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Heart failure; plasma volume; sodium chloride; sodium potassium chloride symporter inhibitors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CHLORIDE; FUROSEMIDE; LOOP DIURETIC AGENT; BIOLOGICAL MARKER; CHLORATE; SODIUM CHLORATE;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BODY WEIGHT; BODY WEIGHT LOSS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ARREST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW RISK PATIENT; MALE; PROSPECTIVE STUDY; URINALYSIS; VISUAL ANALOG SCALE; VOLUMETRY; AGED; DOSE RESPONSE; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME; URINE;

AGED; BIOMARKERS; CHLORATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 85031429012     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.1080/00015385.2017.1385152     Document Type: Article

References (18)

1. Fonarow GC, Corday E., Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev. 2004;9:179–185.
2. Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265–272.
3. Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54–62.
4. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–1069.
5. Verbrugge FH, Mullens W, Tang WH., Management of cardio-renal syndrome and diuretic resistance. Curr Treat Options Cardiovasc Med. 2016;18:11.
6. Singh D, Shrestha K, Testani JM, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20:392–399.
7. Verbrugge FH, Nijst P, Dupont M, et al. Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ Heart Fail. 2014;7:766–772.
8. Verbrugge FH, Steels P, Grieten L, et al. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol. 2015;65:480–492.
9. Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261–270.
10. Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35:1284–1293.
11. Voors AA, Davison BA, Teerlink JR, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome–an analysis from RELAX-AHF. Eur J Heart Fail. 2014;16:1230–1240.
12. Ter Maaten JM, Dunning AM, Valente MA, et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J. 2015;170:313–321.
13. Verbrugge FH, Dupont M, Bertrand PB, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70:265–273.
14. Aronson D, Burger AJ., Diuretic response: clinical and hemodynamic predictors and relation to clinical outcome. J Card Fail. 2016;22:193–200.
15. Ali SS, Olinger CC, Sobotka PA, et al. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail. 2009;15:1–4.
16. Vaduganathan M, Goldsmith SR, Senni M, et al. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. Eur J Heart Fail. 2016;18:185–191.
17. Verbrugge FH., Decongestion: more than meets the eye! Eur J Heart Fail. 2016;18:192–194.
18. Testani JM, Hanberg JS, Cheng S, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9:e002370.